Successfully switching acetylcholinesterase inhibitor therapy in probable Lewy body dementia.

Abstract

Lewy body disease is a common cause of dementia. Pharmacological therapies for the symptomatic treatment of this disorder are few and largely consist of acetylcholinesterase inhibitors. No guidelines exist regarding poor response or intolerability with such medications. This report discusses a case of an elderly woman with a diagnosis of probable Lewy body dementia who had significant improvement with donepezil but discontinued it due to side effects. She was switched to rivastigmine which she tolerated and which had a similar clinical response. The process of switching is discussed in light of the lack of specific guidelines.

• Authors: Fahad Khalifa Alwahhabi
• Journal: Journal of psychopharmacology (Oxford, England) (J Psychopharmacol) Vol. 19 Issue 2 Pg. 214-6 (Mar 2005) ISSN: 0269-8811 [Print] United States
• PMID: 15728444 (Publication Type: Case Reports, Journal Article)

Chemical References

• Cholinesterase Inhibitors
• Indans
• Neuroprotective Agents
• Phenylcarbamates
• Piperidines
• Donepezil
• Rivastigmine

Topics

• Aged
• Cholinesterase Inhibitors (adverse effects, therapeutic use)
• Donepezil
• Female
• Humans
• Indans (adverse effects, therapeutic use)
• Lewy Body Disease (drug therapy, psychology)
• Neuroprotective Agents (therapeutic use)
• Phenylcarbamates (therapeutic use)
• Piperidines (adverse effects, therapeutic use)
• Rivastigmine
• Sweating (drug effects)